Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
2017 · New England Journal of Medicine · 3,053 citations
https://doi.org/10.1056/nejmoa1607427
J
Jonathan Strosberg
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
430
Papers
21.1K
Citations
70
h-index
192
i10-index
Jonathan Strosberg is an academic researcher from Moffitt Cancer Center. The author has contributed to research in topics: Neuroendocrine Tumor Research Advances & Lung Cancer Research Studies & Neuroblastoma Research and Treatments. The author has an h-index of 70, co-authored 366 publications.
ORCID: 0000-0001-8405-218XPapers by this author
worksImpact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
2020 · European Journal of Nuclear Medicine and Molecular Imaging · 120 citations
https://doi.org/10.1007/s00259-020-04709-x
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
2024 · New England Journal of Medicine · 111 citations
https://doi.org/10.1056/nejmoa2403991
Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
2018 · Annals of Oncology · 74 citations
https://doi.org/10.1093/annonc/mdy293.001
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
2024 · ESMO Open · 16 citations
https://doi.org/10.1016/j.esmoop.2024.102386
<scp>PRRT</scp> in high‐grade digestive neuroendocrine neoplasms ( <scp>NET G3</scp> and <scp>NEC</scp> )
2024 · Journal of Neuroendocrinology · 11 citations
https://doi.org/10.1111/jne.13443
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat